PMID- 16100159
OWN - NLM
STAT- MEDLINE
DCOM- 20050906
LR  - 20131121
IS  - 0012-3692 (Print)
IS  - 0012-3692 (Linking)
VI  - 128
IP  - 2
DP  - 2005 Aug
TI  - Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes 
      in patients with pulmonary arterial hypertension.
PG  - 714-9
AB  - OBJECTIVE: To determine whether lipid microspheres containing prostaglandin E1 
      (lipo-PGE1) improve pulmonary hemodynamics and clinical outcomes in patients with 
      pulmonary arterial hypertension (PAH). METHODS: Forty-nine patients with PAH (8 
      patients with primary pulmonary hypertension, 21 patients with collagen vascular 
      disease, 20 patients with congenital systemic-to-pulmonary shunts) were randomly 
      classified into a conventional therapy group (n = 22) or a group receiving 
      lipo-PGE1 plus conventional drugs (lipo-PGE1 group; n = 27). Echocardiographic 
      pulmonary parameters, New York Heart Association (NYHA) functional class, and 
      Bruce treadmill test results for exercise capacity were recorded before and after 
      treatment. RESULTS: After 2 weeks of treatment with lipo-PGE1 (10 microg bid for 
      14 days), there were significant improvements in the values (+/- SD) for systolic 
      pulmonary arterial pressure (SPAP) [76.9 +/- 27.9 mm Hg vs 66.5 +/- 22.8 mm Hg, p 
      < 0.001]; total pulmonary resistance (27.2 +/- 13.3 dyne.s.cm(-5) vs 20.2 +/- 
      10.7 dyne.s.cm(-5), p < 0.001); left ventricular ejection fraction (58.7 +/- 9.6% 
      vs 64.4 +/- 6.8%, p < 0.001); and cardiac output (3.1 +/- 0.8 L/min vs 3.7 +/- 
      1.1 L/min, p < 0.01). The NYHA functional class decreased from 3.0 +/- 0.6 to 2.5 
      +/- 0.6 (p < 0.001), and the exercise capacity increased from 2.8 +/- 1.0 to 4.3 
      +/- 1.3 metabolic equivalents (MET) [p < 0.001]. Compared with the conventional 
      therapy group, the lipo-PGE(1) group achieved significant reduction of SPAP (10.4 
      +/- 10.3 mm Hg vs 2.2 +/- 5.6 mm Hg, p = 0.002) and a significant elevation of 
      exercise capacity (1.5 +/- 0.9 MET vs 0.6 +/- 1.1 MET, p = 0.018). CONCLUSION: 
      Lipo-PGE1 can decrease pulmonary artery pressure and increase exercise capacity 
      in patients with PAH.
FAU - Shen, Jieyan
AU  - Shen J
AD  - Department of Cardiology, Shanghai Second Medical University--Affiliated Renji 
      Hospital, 1630 Dong Fang Rd, Shanghai 200127, Republic of China. 
      Shenjieyan_66@hotmail.com
FAU - He, Ben
AU  - He B
FAU - Wang, Binyao
AU  - Wang B
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Chest
JT  - Chest
JID - 0231335
RN  - 0 (Lipids)
RN  - 0 (Vasodilator Agents)
RN  - F5TD010360 (Alprostadil)
SB  - IM
MH  - Alprostadil/*administration & dosage/pharmacology
MH  - Drug Delivery Systems
MH  - Female
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy/*physiopathology
MH  - Lipids
MH  - Male
MH  - Microspheres
MH  - Middle Aged
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Vasodilator Agents/*administration & dosage/pharmacology
EDAT- 2005/08/16 09:00
MHDA- 2005/09/07 09:00
CRDT- 2005/08/16 09:00
PHST- 2005/08/16 09:00 [pubmed]
PHST- 2005/09/07 09:00 [medline]
PHST- 2005/08/16 09:00 [entrez]
AID - S0012-3692(15)50417-0 [pii]
AID - 10.1378/chest.128.2.714 [doi]
PST - ppublish
SO  - Chest. 2005 Aug;128(2):714-9. doi: 10.1378/chest.128.2.714.